寶鷹股份(002047.SZ):向22名激勵對象授予1300萬份股票期權
格隆匯 12 月 3日丨寶鷹股份(002047.SZ)公佈,公司於2020年12月3日分別召開第七屆董事會第七次會議和第七屆監事會第五次會議,審議通過了《關於向激勵對象授予預留股票期權的議案》,根據《上市公司股權激勵管理辦法》、《深圳市寶鷹建設控股集團股份有限公司第一期股票期權激勵計劃(草案)》等的相關規定及公司2019年第四次臨時股東大會的授權,董事會認為公司第一期股票期權激勵計劃規定的預留股票期權的授予條件已經成就,同意以2020年12月3日作為此次預留股票期權的授予日,向22名激勵對象授予1300萬份股票期權,預留股票期權行權價格為人民幣5.00元/份。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.